Javascript must be enabled to continue!
Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital
View through CrossRef
OBJECTIVE
To determine if it is possible to exclude staging bone scans in a greater proportion of patients if more consideration is given to T stage and Gleason score, as recent guidelines from the National Institute of Clinical Excellence state that routine staging bone scans for prostate cancer are unnecessary in patients with a prostate specific antigen level (PSA) of < 10 ng/mL and Gleason scores of < 8.
PATIENTS AND METHODS
We identified a cohort of consecutive patients with untreated prostate cancer who had a staging isotope bone scan between 1 January 1995 and 31 December 2000, who were not on hormone therapy, who had their PSA estimated within 30 days of the scan, and who had histologically confirmed prostate cancer on biopsy reviewed at the Royal Marsden. Data were analysed according to Gleason score, major Gleason grade, clinical T‐stage and PSA level.
RESULTS
In all, 420 patients were identified who fulfilled the criteria for inclusion; 67 scans (16%, 95% confidence interval, CI, 13–20%) were positive. Of the 187 scans taken in patients with a PSA level of ≤ 20 ng/mL, stage < T4 and Gleason < 8 (with major Gleason grade < 4), two (1%, 0.3–4%) were reported as positive, giving a negative predictive value of 99% (95% CI 98.5–99.5%) for these criteria for avoiding the need for staging bone scans. In 116 patients (28%) with Gleason score 7, of whom 28 (24%) had positive scans, there was a statistically significant association between positive scans and a major Gleason pattern of 4 compared with 3.
CONCLUSIONS
Isotope bone scans are an unnecessary part of staging of prostate cancer if the PSA level is ≤ 20 ng/mL, stage < T4 and Gleason score < 8, and should be omitted unless the major Gleason pattern is 4. The present results suggest that by considering the Gleason score and T stage, a larger proportion of patients with prostate cancer than previously thought could avoid a staging bone scan.
Title: Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital
Description:
OBJECTIVE
To determine if it is possible to exclude staging bone scans in a greater proportion of patients if more consideration is given to T stage and Gleason score, as recent guidelines from the National Institute of Clinical Excellence state that routine staging bone scans for prostate cancer are unnecessary in patients with a prostate specific antigen level (PSA) of < 10 ng/mL and Gleason scores of < 8.
PATIENTS AND METHODS
We identified a cohort of consecutive patients with untreated prostate cancer who had a staging isotope bone scan between 1 January 1995 and 31 December 2000, who were not on hormone therapy, who had their PSA estimated within 30 days of the scan, and who had histologically confirmed prostate cancer on biopsy reviewed at the Royal Marsden.
Data were analysed according to Gleason score, major Gleason grade, clinical T‐stage and PSA level.
RESULTS
In all, 420 patients were identified who fulfilled the criteria for inclusion; 67 scans (16%, 95% confidence interval, CI, 13–20%) were positive.
Of the 187 scans taken in patients with a PSA level of ≤ 20 ng/mL, stage < T4 and Gleason < 8 (with major Gleason grade < 4), two (1%, 0.
3–4%) were reported as positive, giving a negative predictive value of 99% (95% CI 98.
5–99.
5%) for these criteria for avoiding the need for staging bone scans.
In 116 patients (28%) with Gleason score 7, of whom 28 (24%) had positive scans, there was a statistically significant association between positive scans and a major Gleason pattern of 4 compared with 3.
CONCLUSIONS
Isotope bone scans are an unnecessary part of staging of prostate cancer if the PSA level is ≤ 20 ng/mL, stage < T4 and Gleason score < 8, and should be omitted unless the major Gleason pattern is 4.
The present results suggest that by considering the Gleason score and T stage, a larger proportion of patients with prostate cancer than previously thought could avoid a staging bone scan.
Related Results
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract
Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract
The human olfactomedin 4 gene (OLFM4) encodes an olfactomedin-related glycoprotein, which our group first cloned and characterized in myeloid cells and mapp...
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract
BACKGROUND: Multiple steps and factors are involved in prostate carcinogenesis and tumor progression. The early studies have found that tumor-associated mac...
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
ImportanceAdvocates for removing the cancer label from grade group 1 (GG1) prostate cancer detected on biopsy primarily base their argument on the observation that when only GG1 is...
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Background: Early prostate cancer antigen (EPCA), a nuclear matrix protein, has recently been recommended as a hopeful biomarker for early prostate carcinogenesis. Objectives: To e...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Abstract 1992: Mesenchymal stem cell-derived interleukin-28 can drive the selection of apoptosis resistant bone metastatic prostate cancer
Abstract 1992: Mesenchymal stem cell-derived interleukin-28 can drive the selection of apoptosis resistant bone metastatic prostate cancer
Abstract
Bone metastatic prostate cancer is painful and incurable. We believe that understanding the interactions of tumor cells and the surrounding stromal cells...

